Similar companies
Did Liminatus Pharma Beat Earnings?
Liminatus Pharma (LIMN) reported Q2 '25 revenue of $0, with reported EPS of $0.01.
AltIndex tracks earnings alongside 25+ alternative data signals that can move ahead of the report — Liminatus Pharma’s job postings, web traffic, and employee business outlook. See the full LIMN stock analysis or the earnings calendar for upcoming reports.
Liminatus Pharma Quarterly Financial Trends
| Metric | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net income | -640,000 | -870,000 | -260 | — | -1.8M | -8.2M | -1.1M | -1.4M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS | — | — | — | $0.01 | — | — | — | — |
Liminatus Pharma Earnings Trend Analysis
Over the eight quarters from Q3 '24 to Q2 '26, Liminatus Pharma’s quarterly revenue moved from $0 to $0.
When Is Liminatus Pharma’s Next Earnings Date?
Liminatus Pharma reports earnings on a quarterly schedule. Its most recent report covered Q2 '25. For the confirmed upcoming date — and every other company reporting soon — see the LIMN earnings calendar.
Frequently Asked Questions: Liminatus Pharma Earnings
Liminatus Pharma's next earnings date has not been confirmed yet. See the earnings calendar for all upcoming reports.
Liminatus Pharma reported Q2 '25 EPS of $0.01 on revenue of $0. Liminatus Pharma reported EPS of $0.01.
Liminatus Pharma reported Q2 '25 revenue of $0.
Signals like job postings, web traffic, and employee sentiment reflect business activity in real time and can move before quarterly results are reported. AltIndex combines them with 25+ others in the LIMN AI Score.
